Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BO-112 + nivolumab + radiotherapy
- Development stage
- Unknown
- Lead developer
- Highlight Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
This combination therapy consists of BO-112, an intratumoral viral mimetic, administered alongside the PD-1 inhibitor nivolumab and stereotactic ablative radiotherapy (SABR). BO-112 is a nanoplexed formulation of polyinosinic:polycytidylic acid (poly I:C) and polyethyleneimine that acts as a double-stranded RNA analog. It triggers an immune response by activating Toll-like receptor 3 (TLR3), melanoma differentiation-associated protein 5 (MDA-5), and protein kinase R (PKR), effectively mimicking a viral infection within the tumor microenvironment. This activation leads to dendritic cell maturation, increased CD8+ T-cell infiltration, and the induction of type I interferons. The combination is specifically being evaluated in Phase Ib/II clinical trials for patients with metastatic non-small cell lung cancer (NSCLC) who have progressed on prior PD-1/PD-L1 checkpoint inhibitor therapy, aiming to overcome resistance by turning "cold" tumors "hot."
- Brand names
- Opdivo
- Other names
- BO-112 + nivolumab + SABR
02
Targets
IFIH1 (MDA5)EIF2AK2 (Interferon-induced protein kinase R)PDCD1 (Programmed cell death protein 1 receptor)TLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on BO-112 + nivolumab + radiotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BO-112 + nivolumab + radiotherapy.